Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about VRCA, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Part 1: VP-315 3 Day Dosing/Week | Basal Cell Carcinoma | Phase 2 · NCT05188729 | Completed |
| Part 2: VP-315 2 Day Dosing/Week - Split Dose | Basal Cell Carcinoma | Phase 2 · NCT05188729 | Completed |
| Part 2: VP-315 3 Day Dosing/Week - Loading Dose | Basal Cell Carcinoma | Phase 2 · NCT05188729 | Completed |
| Part 2: VP-315 3 Day Dosing/Week - No Loading… | Basal Cell Carcinoma | Phase 2 · NCT05188729 | Completed |
| Part 2: VP-315 3 Day Dosing/Week - Split Dose | Basal Cell Carcinoma | Phase 2 · NCT05188729 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
VRCA holds $11.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $9.2M/quarter from operations, an estimated runway of 3.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 85 · High
Based on the current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding, the Company has concluded that substantial doubt exists regarding its ability to continue as a going concern within one year after the date these consolidated financial…10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VRCA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Paul B Manning Director, 10% owner · +687,690 options |
Insider | 4,316,285 | 25.13% | 2025-11-25 |
| BKB Growth Investments, LLC 10% owner |
Insider | 3,348,372 | 19.49% | 2025-11-25 |
| John A III Stalfort Director · +561,797 options |
Insider | 1,873,800 | 10.91% | 2024-11-22 |
| Caligan Partners LP See Remarks |
Insider | 923,910 | 5.38% | 2025-12-26 |
| Ted White PRESIDENT AND CEO, Director |
Insider | 278,789 | 1.62% | 2023-08-24 |
| Jayson Rieger CEO and President, Director · +1.53M options |
Insider | 207,838 | 1.21% | 2026-08-14 |
| Joe Bonaccorso CHIEF COMMERCIAL OFFICER |
Insider | 187,738 | 1.09% | 2023-08-24 |
| Christopher G. Hayes CHIEF LEGAL OFFICER · +250,000 options |
Insider | 176,458 | 1.03% | 2025-03-14 |
| Terry Kohler CHIEF FINANCIAL OFFICER |
Insider | 125,000 | 0.73% | 2023-08-24 |
| Gary Goldenberg Chief Medical Officer |
Insider | 120,110 | 0.70% | 2023-08-24 |
| David Zawitz Chief Operating Officer · +1.12M options |
Insider | 27,000 | 0.16% | 2026-08-17 |
| John J. Kirby Interim CFO · +884 options |
Insider | 23,962 | 0.14% | 2026-08-18 |
Share count 17,178,786 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VRCA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →